Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eli Lilly gets FDA approval of Tauvid in patients evaluated for Alzheimer's » 19:23
05/28/20
05/28
19:23
05/28/20
19:23
LLY

Eli Lilly

$150.63 /

+5.02 (+3.45%)

TAUVID, a radioactive…

TAUVID, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease, or AD. A neuropathological diagnosis of AD requires the demonstration of the presence of both beta-amyloid neuritic plaques and tau NFTs in the brain. TAUVID is the first and only approved diagnostic agent to image tau NFTs in the brain. Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, developed TAUVID and AMYVID to provide physicians with meaningful information on the presence of both pathologies to aid the evaluation of patients suspected of having AD. Availability of TAUVID will initially be limited and will expand in response to commercial demand and payor reimbursement.

ShowHide Related Items >><<
LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

Hot Stocks
Merck, Eisai announce new data from KEYTRUDA plus LENVIMA trials » 18:38
05/28/20
05/28
18:38
05/28/20
18:38
MRK

Merck

$79.02 /

+1.46 (+1.88%)

Merck and Eisai announced…

Merck and Eisai announced new data from analyses of two trials evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. In the KEYNOTE-524/Study 116 and KEYNOTE-146/Study 111 trials, the KEYTRUDA plus LENVIMA combination demonstrated clinically meaningful objective response rates in patients with unresectable hepatocellular carcinoma with no prior systemic therapy and in patients with metastatic clear cell renal cell carcinoma who progressed following immune checkpoint inhibitor therapy, respectively. "The tumor response rates demonstrated with KEYTRUDA plus LENVIMA in these studies underscore the potential of this combination regimen in certain types of hepatocellular and renal cell carcinoma," said Dr. Jonathan Cheng, Vice President, Oncology Clinical Research, Merck Research Laboratories. "KEYTRUDA plus LENVIMA is an important pillar of our broad oncology research program, and we continue to advance the study of the combination across multiple types of cancers and stages of disease." "As data from our combination trials continue to read out, our enthusiasm for and belief in the potential of KEYTRUDA plus LENVIMA are strengthened by the growing body of evidence observed in multiple advanced cancers," said Dr. Takashi Owa, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. "Our ongoing clinical study efforts on this combination exemplify our commitment to following the science and exploring possible solutions for patients affected by difficult-to-treat cancers."

ShowHide Related Items >><<
MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

Hot Stocks
Merck study shows KEYTRUDA reduced risk of progression, death by 40% » 17:02
05/28/20
05/28
17:02
05/28/20
17:02
MRK

Merck

$79.02 /

+1.46 (+1.88%)

Merck announced the first…

Merck announced the first presentation of results from KEYNOTE-177, a Phase 3 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer. In this pivotal study, KEYTRUDA monotherapy significantly reduced the risk of disease progression or death by 40% and showed a median progression-free survival of 16.5 months compared with 8.2 months for patients treated with chemotherapy, a current standard of care in this patient population. As previously announced, the study will continue without changes to evaluate overall survival, the other dual primary endpoint. These results were selected for presentation on Sunday, May 31, 2020 in the plenary session of the virtual scientific program of the 2020 American Society of Clinical Oncology Annual Meeting. "For many years, the standard of care for the first-line treatment of patients with MSI-H colorectal cancer has been the combination of mFOLFOX6 plus bevacizumab. This is the first time a single-agent, anti-PD-1 therapy demonstrated a superior, statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy for these patients," said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "There is an unmet need for new treatment options in the first-line setting that may provide sustained, long-term improvements in outcomes for patients with MSI-H colorectal cancer. We are grateful to have the opportunity to present these practice-changing findings at the plenary session of this year's ASCO."

ShowHide Related Items >><<
MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

On The Fly
Alexion rises as documents suggest settlement of Amgen patent challenge » 11:41
05/28/20
05/28
11:41
05/28/20
11:41
ALXN

Alexion

$115.45 /

+9.28 (+8.74%)

, AMGN

Amgen

$224.79 /

-0.02 (-0.01%)

, SNY

Sanofi

$48.89 /

+1.38 (+2.90%)

, REGN

Regeneron

$566.53 /

+22.52 (+4.14%)

Shares of Alexion (ALXN)…

Open Full Text

ShowHide Related Items >><<
SNY Sanofi
$48.89 /

+1.38 (+2.90%)

REGN Regeneron
$566.53 /

+22.52 (+4.14%)

AMGN Amgen
$224.79 /

-0.02 (-0.01%)

ALXN Alexion
$115.45 /

+9.28 (+8.74%)

ALXN Alexion
$115.45 /

+9.28 (+8.74%)

05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$224.79 /

-0.02 (-0.01%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
SNY Sanofi
$48.89 /

+1.38 (+2.90%)

05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 UBS
Sanofi price target lowered to EUR 101 from EUR 103 at UBS
05/26/20 Piper Sandler
Piper remains buyer of Regeneron, ups target to $630 on buyback accretion
REGN Regeneron
$566.53 /

+22.52 (+4.14%)

05/28/20 Barclays
Regeneron price target raised to $615 from $530 at Barclays
05/26/20
Fly Intel: Top five analyst upgrades
SNY Sanofi
$48.89 /

+1.38 (+2.90%)

REGN Regeneron
$566.53 /

+22.52 (+4.14%)

AMGN Amgen
$224.79 /

-0.02 (-0.01%)

ALXN Alexion
$115.45 /

+9.28 (+8.74%)

  • 27
    May
SNY Sanofi
$48.89 /

+1.38 (+2.90%)

REGN Regeneron
$566.53 /

+22.52 (+4.14%)

AMGN Amgen
$224.79 /

-0.02 (-0.01%)

ALXN Alexion
$115.45 /

+9.28 (+8.74%)

SNY Sanofi
$48.89 /

+1.38 (+2.90%)

AMGN Amgen
$224.79 /

-0.02 (-0.01%)

ALXN Alexion
$115.45 /

+9.28 (+8.74%)

SNY Sanofi
$48.89 /

+1.38 (+2.90%)

REGN Regeneron
$566.53 /

+22.52 (+4.14%)

ALXN Alexion
$115.45 /

+9.28 (+8.74%)

Periodicals
Elliott says Alexion settlement may 'leave the door open' for strategic review » 09:15
05/28/20
05/28
09:15
05/28/20
09:15
AMGN

Amgen

$224.81 /

+2.55 (+1.15%)

, ALXN

Alexion

$106.17 /

+3.4 (+3.31%)

A spokesperson for…

A spokesperson for activist Elliott Management regarding the potential inter partes review settlement between Amgen (AMGN) and Alexion Pharmaceutical (ALXN): "Although Elliott believes the IPR overhang was overblown, a sensible settlement would remove a significant source of uncertainty and leave the door open for the Company to explore strategic alternatives without further delay, the value maximising pathway for the Company in Elliott's view." In December, Alexion announced that even though Elliott recommended it "immediately launch a proactive sale process," its board "unanimously decided that conducting a proactive sale process would not be in the best interest of shareholders and the patients we serve at this time." Shares of Alexion are up 7% to $113.53 in premarket trading.

ShowHide Related Items >><<
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ALXN Alexion
$106.17 /

+3.4 (+3.31%)

05/26/20 BMO Capital
BMO Capital still sees favorable risk/reward in Alexion following Argenx news
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

On The Fly
Fly Intel: Pre-market Movers » 09:12
05/28/20
05/28
09:12
05/28/20
09:12
ALXN

Alexion

$106.17 /

+3.4 (+3.31%)

, AMGN

Amgen

$224.81 /

+2.55 (+1.15%)

, BA

Boeing

$149.46 /

+4.77 (+3.30%)

, DLTR

Dollar Tree

$87.43 /

+2.26 (+2.65%)

, LL

Lumber Liquidators

$9.53 /

+0.79 (+9.04%)

, TGI

Triumph Group

$8.18 /

+1.92 (+30.67%)

, CSIQ

Canadian Solar

$19.29 /

+0.265 (+1.39%)

, WDAY

Workday

$170.10 /

+1.72 (+1.02%)

, DG

Dollar General

$186.80 /

+6.41 (+3.55%)

, BURL

Burlington Stores

$210.31 /

+1.44 (+0.69%)

, ANF

Abercrombie & Fitch

$13.08 /

+0.41 (+3.24%)

, HPQ

HP Inc.

$17.13 /

+0.06 (+0.35%)

, TWTR

Twitter

$33.06 /

-0.96 (-2.82%)

, FB

Facebook

$229.17 /

-2.97 (-1.28%)

, IOVA

Iovance Biotherapeutics

$38.12 /

+0.66 (+1.76%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TGI Triumph Group
$8.18 /

+1.92 (+30.67%)

LL Lumber Liquidators
$9.53 /

+0.79 (+9.04%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

FB Facebook
$229.17 /

-2.97 (-1.28%)

DLTR Dollar Tree
$87.43 /

+2.26 (+2.65%)

DG Dollar General
$186.80 /

+6.41 (+3.55%)

CSIQ Canadian Solar
$19.29 /

+0.265 (+1.39%)

BURL Burlington Stores
$210.31 /

+1.44 (+0.69%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ANF Abercrombie & Fitch
$13.08 /

+0.41 (+3.24%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/26/20 BMO Capital
BMO Capital still sees favorable risk/reward in Alexion following Argenx news
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
BA Boeing
$149.46 /

+4.77 (+3.30%)

05/28/20 BMO Capital
Hexcel price target raised to $45 from $37 at BMO Capital
05/22/20 Canaccord
Boeing price target lowered to $155 from $175 at Canaccord
05/20/20 RBC Capital
RBC starts Boeing at Outperform on favorable risk/reward profile
05/20/20 RBC Capital
Boeing initiated with an Outperform at RBC Capital
DLTR Dollar Tree
$87.43 /

+2.26 (+2.65%)

05/26/20 Deutsche Bank
Dollar Tree price target raised to $97 from $87 at Deutsche Bank
05/18/20 Gordon Haskett
Colgate, Dollar Tree speculated as possible Peltz targets by Gordon Haskett
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Goldman Sachs
Dollar Tree initiated with a Buy at Goldman Sachs
LL Lumber Liquidators
$9.53 /

+0.79 (+9.04%)

01/21/20
Fly Intel: Top five analyst downgrades
01/21/20 Morgan Stanley
Lumber Liquidators downgraded to Underweight from Equal Weight at Morgan Stanley
12/04/19 Wedbush
Floor & Decor to see earnings boost from tariff exclusion, says Wedbush
09/13/19 Raymond James
Lumber Liquidators price target raised to $14 from $10 at Raymond James
TGI Triumph Group
$8.18 /

+1.92 (+30.67%)

03/20/20 BofA
BofA double downgrades Triumph, slashes price target amid COVID-19 impact
03/20/20 BofA
Triumph Group downgraded to Underperform from Buy at BofA
03/11/20 Goldman Sachs
Goldman cuts targets across Aerospace coverage for COVID-19 impact
08/23/19
Fly Intel: Top five analyst downgrades
CSIQ Canadian Solar
$19.29 /

+0.265 (+1.39%)

03/25/20 Roth Capital
ITC extension 'NOT' in Phase 3 coronavirus rescue package, says Roth Capital
10/07/19 Goldman Sachs
Goldman says U.S. solar makers should benefit from end of bifacial exemption
08/16/19 Roth Capital
Canadian Solar price target raised to $32 from $27 at Roth Capital
WDAY Workday
$170.10 /

+1.72 (+1.02%)

05/28/20 Needham
Workday price target raised to $200 from $175 at Needham
05/28/20 Wells Fargo
Workday price target raised to $195 from $155 at Wells Fargo
05/28/20 Wedbush
Workday price target lowered to $196 from $206 at Wedbush
05/28/20 Deutsche Bank
Workday price target raised to $180 from $150 at Deutsche Bank
DG Dollar General
$186.80 /

+6.41 (+3.55%)

05/26/20 Deutsche Bank
Dollar General price target raised to $187 from $159 at Deutsche Bank
05/18/20 Goldman Sachs
Dollar General initiated with a Buy at Goldman Sachs
04/30/20
Fly Intel: Top five analyst downgrades
BURL Burlington Stores
$210.31 /

+1.44 (+0.69%)

05/11/20 Nomura Instinet
Burlington Stores price target raised to $190 from $170 at Nomura Instinet
03/24/20 Citi
Burlington Stores price target lowered to $205 from $260 at Citi
03/19/20 Nomura Instinet
Burlington Stores price target lowered to $170 from $252 at Nomura Instinet
03/11/20
Fly Intel: Top five analyst upgrades
ANF Abercrombie & Fitch
$13.08 /

+0.41 (+3.24%)

04/03/20
Fly Intel: Top five analyst upgrades
04/03/20 B. Riley FBR
B. Riley FBR upgrades Abercrombie on ability to 'weather the storm'
04/03/20 B. Riley FBR
Abercrombie & Fitch upgraded to Buy from Neutral at B. Riley FBR
03/24/20 Wedbush
Microsoft, Alphabet among stocks in Wedbush's Shopping List
HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

05/28/20 JPMorgan
HP Inc. downgraded to Neutral from Overweight at JPMorgan
05/26/20 Credit Suisse
HP Inc. price target lowered to $17 from $22 at Credit Suisse
05/22/20 JPMorgan
HP shares worth owning through downturn, says JPMorgan
04/27/20 Loop Capital
Xerox, Park City, NetApp, HP Enterprise cut to Hold from Buy at Loop Capital
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
05/01/20
Fly Intel: Top five analyst downgrades
05/01/20 Deutsche Bank
Twitter price target raised to $28 from $22 at Deutsche Bank
FB Facebook
$229.17 /

-2.97 (-1.28%)

05/27/20 Citi
Facebook price target raised to $275 from $245 at Citi
05/21/20 Stifel
Facebook price target raised to $260 from $245 at Stifel
05/20/20 Deutsche Bank
Facebook Shops could be $30B revenue opportunity, says Deutsche Bank
IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

05/28/20 Piper Sandler
Iovance melanoma data 'fully supportive of approval,' says Piper Sandler
04/29/20 Oppenheimer
Iovance Biotherapeutics price target raised to $43 from $35 at Oppenheimer
04/29/20 H.C. Wainwright
Iovance Biotherapeutics price target raised to $48 from $36 at H.C. Wainwright
04/27/20 Piper Sandler
AACR abstract for Moffitt study positive for Iovance, says Piper Sandler
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TGI Triumph Group
$8.18 /

+1.92 (+30.67%)

LL Lumber Liquidators
$9.53 /

+0.79 (+9.04%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

FB Facebook
$229.17 /

-2.97 (-1.28%)

DLTR Dollar Tree
$87.43 /

+2.26 (+2.65%)

DG Dollar General
$186.80 /

+6.41 (+3.55%)

CSIQ Canadian Solar
$19.29 /

+0.265 (+1.39%)

BURL Burlington Stores
$210.31 /

+1.44 (+0.69%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ANF Abercrombie & Fitch
$13.08 /

+0.41 (+3.24%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

  • 29
    May
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

FB Facebook
$229.17 /

-2.97 (-1.28%)

DLTR Dollar Tree
$87.43 /

+2.26 (+2.65%)

CSIQ Canadian Solar
$19.29 /

+0.265 (+1.39%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ANF Abercrombie & Fitch
$13.08 /

+0.41 (+3.24%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

LL Lumber Liquidators
$9.53 /

+0.79 (+9.04%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

FB Facebook
$229.17 /

-2.97 (-1.28%)

DLTR Dollar Tree
$87.43 /

+2.26 (+2.65%)

DG Dollar General
$186.80 /

+6.41 (+3.55%)

CSIQ Canadian Solar
$19.29 /

+0.265 (+1.39%)

BURL Burlington Stores
$210.31 /

+1.44 (+0.69%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ANF Abercrombie & Fitch
$13.08 /

+0.41 (+3.24%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

LL Lumber Liquidators
$9.53 /

+0.79 (+9.04%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

FB Facebook
$229.17 /

-2.97 (-1.28%)

DLTR Dollar Tree
$87.43 /

+2.26 (+2.65%)

DG Dollar General
$186.80 /

+6.41 (+3.55%)

CSIQ Canadian Solar
$19.29 /

+0.265 (+1.39%)

BURL Burlington Stores
$210.31 /

+1.44 (+0.69%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ANF Abercrombie & Fitch
$13.08 /

+0.41 (+3.24%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

Recommendations
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler » 09:08
05/28/20
05/28
09:08
05/28/20
09:08
ALXN

Alexion

$106.17 /

+3.4 (+3.31%)

, AMGN

Amgen

$224.81 /

+2.55 (+1.15%)

, SNY

Sanofi

$47.51 /

+0.25 (+0.53%)

, REGN

Regeneron

$544.01 /

-1.21 (-0.22%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Alexion Pharmaceuticals (ALXN) following news of an impending settlement of Amgen's (AMGN) inter partes review challenge for three U.S. Soliris patents, according to documents posted by the Patent Trial and Appeal Board. A settlement would be a "deck-clearing event" that could also make the Alexion "story cleaner for an acquirer," Raymond tells investors in a research note. Given Elliott Management's involvement and this week's news that Sanofi (SNY) is monetizing its Regeneron (REGN) stake, "this possibility has to be front of mind," says the analyst. Raymond wonders why Alexion would settle now, three months before the PTAB's written decision was due. One possible consideration for Alexion "was to clear the deck to make the story cleaner for an acquirer," contends Raymond. The stock in premarket trading is up 7% to $114.00.

ShowHide Related Items >><<
SNY Sanofi
$47.51 /

+0.25 (+0.53%)

REGN Regeneron
$544.01 /

-1.21 (-0.22%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/26/20 BMO Capital
BMO Capital still sees favorable risk/reward in Alexion following Argenx news
05/26/20 Piper Sandler
Piper stays Overweight Alexion after Argenx data, says comps 'near impossible'
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
SNY Sanofi
$47.51 /

+0.25 (+0.53%)

05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 UBS
Sanofi price target lowered to EUR 101 from EUR 103 at UBS
05/26/20 Piper Sandler
Piper remains buyer of Regeneron, ups target to $630 on buyback accretion
05/26/20 SVB Leerink
Sanofi overhang removed, Regeneron capital structure improving, says SVB Leerink
REGN Regeneron
$544.01 /

-1.21 (-0.22%)

05/28/20 Barclays
Regeneron price target raised to $615 from $530 at Barclays
05/26/20
Fly Intel: Top five analyst upgrades
05/26/20 RBC Capital
BioMarin among Sanofi's most intriguing potential targets, says RBC Capital
SNY Sanofi
$47.51 /

+0.25 (+0.53%)

REGN Regeneron
$544.01 /

-1.21 (-0.22%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

  • 27
    May
SNY Sanofi
$47.51 /

+0.25 (+0.53%)

REGN Regeneron
$544.01 /

-1.21 (-0.22%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

SNY Sanofi
$47.51 /

+0.25 (+0.53%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

SNY Sanofi
$47.51 /

+0.25 (+0.53%)

REGN Regeneron
$544.01 /

-1.21 (-0.22%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

Recommendations
Alexion settlement may yield upside surprise, says Cowen » 08:48
05/28/20
05/28
08:48
05/28/20
08:48
ALXN

Alexion

$106.17 /

+3.4 (+3.31%)

, AMGN

Amgen

$224.81 /

+2.55 (+1.15%)

Cowen analyst Phil Nadeau…

Cowen analyst Phil Nadeau Noted Alexion (ALXN) and Amgen (AMGN) have reached a settlement in principle in the Soliris IPR challenge. The analyst said most investors assumes Alexion's patents would fall however, he thinks an agreement that preserves some of the term is an upside surprise and his preliminary sensitivity analysis suggests each year the generic entry is pushed past 2022, it is worth $5 per share to Alexion. Nadeau has an Outperform rating and $165 price target on Alexion shares.

ShowHide Related Items >><<
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/26/20 BMO Capital
BMO Capital still sees favorable risk/reward in Alexion following Argenx news
05/26/20 Piper Sandler
Piper stays Overweight Alexion after Argenx data, says comps 'near impossible'
05/26/20 Credit Suisse
Skepticism may create overlooked value in Alexion pipeline, says Credit Suisse
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/04/20 Cantor Fitzgerald
Amgen price target raised to $263 from $255 at Cantor Fitzgerald
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

Recommendations
Alexion, Amgen appear to have agreed to settlement deal, says Stifel » 07:59
05/28/20
05/28
07:59
05/28/20
07:59
ALXN

Alexion

$106.17 /

+3.4 (+3.31%)

, AMGN

Amgen

$224.81 /

+2.55 (+1.15%)

Stifel analyst Paul…

Stifel analyst Paul Matteis noted that Alexion (ALXN) and Amgen (AMGN) requested a trial postponement last night and he views filings with the Patent Trial and Appeal Board as suggesting that the parties appear to have agreed in principle on a settlement in Amgen's three PTAB challenges to Soliris patents. While the terms haven't been disclosed, the "bottom line for the stock" is that this is good news and Alexion shares "will likely deservedly trade higher today," Matteis tells investors. However, he keeps a Hold rating on Alexion as he believes that it is debatable as to whether biosimilar or branded competition is the more salient threat and he would argue for the latter. Additionally, Matteis thinks that so far the company's deals for Syntimmune, Affibody and Stealth "have been disappointing."

ShowHide Related Items >><<
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

05/26/20 BMO Capital
BMO Capital still sees favorable risk/reward in Alexion following Argenx news
05/26/20 Piper Sandler
Piper stays Overweight Alexion after Argenx data, says comps 'near impossible'
05/26/20 Credit Suisse
Skepticism may create overlooked value in Alexion pipeline, says Credit Suisse
05/15/20 H.C. Wainwright
H.C. Wainwright calls Sarepta 'best of breed' after Pfizer DMD data
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/04/20 Cantor Fitzgerald
Amgen price target raised to $263 from $255 at Cantor Fitzgerald
05/01/20 BMO Capital
Amgen price target raised to $291 from $274 at BMO Capital
AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

AMGN Amgen
$224.81 /

+2.55 (+1.15%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

ALXN Alexion
$106.17 /

+3.4 (+3.31%)

Wednesday
Initiation
PDS Biotechnology initiated with a Buy at Alliance Global Partners » 07:05
05/27/20
05/27
07:05
05/27/20
07:05
PDSB

PDS Biotechnology

$1.17 /

-0.01 (-0.85%)

, MRK

Merck

$77.26 /

+0.89 (+1.17%)

Alliance Global Partners…

Alliance Global Partners analyst James Molloy initiated coverage of PDS Biotechnology (PDSB) with a Buy rating and $4 price target. Molloy, who believes that PDS has "an interesting delivery vehicle in Versamune that could be applicable across multiple disease states," sees the company hitting multiple significant development milestones before the second half of 2021. His sum-of-the-parts analysis values PDS0101, which is being studied in combination with Merck's (MRK) checkpoint inhibitor Keytruda for recurrent/metastatic head and neck cancer, at $2.50 per share, Molloy noted.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$1.17 /

-0.01 (-0.85%)

MRK Merck
$77.26 /

+0.89 (+1.17%)

PDSB PDS Biotechnology
$1.17 /

-0.01 (-0.85%)

03/30/20 H.C. Wainwright
PDS Biotechnology downgraded to Neutral from Buy at H.C. Wainwright
03/09/20
Fly Intel: Top five analyst initiations
03/09/20 Noble Capital
PDS Biotechnology initiated with an Outperform at Noble Capital
11/07/19 H.C. Wainwright
PDS Biotechnology Q3 results miss, but studies on track, says H.C. Wainwright
MRK Merck
$77.26 /

+0.89 (+1.17%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
MRK Merck
$77.26 /

+0.89 (+1.17%)

MRK Merck
$77.26 /

+0.89 (+1.17%)

MRK Merck
$77.26 /

+0.89 (+1.17%)

MRK Merck
$77.26 /

+0.89 (+1.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.